REGN Relative Valuation
REGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, REGN is overvalued; if below, it's undervalued.
Historical Valuation
Regeneron Pharmaceuticals Inc (REGN) is now in the Fair zone, suggesting that its current forward PE ratio of 16.14 is considered Fairly compared with the five-year average of 16.07. The fair price of Regeneron Pharmaceuticals Inc (REGN) is between 630.25 to 914.01 according to relative valuation methord.
Relative Value
Fair Zone
630.25-914.01
Current Price：722.47
Fair
16.12
PE
1Y
3Y
5Y
Trailing
Forward
9.73
EV/EBITDA
Regeneron Pharmaceuticals Inc. (REGN) has a current EV/EBITDA of 9.73. The 5-year average EV/EBITDA is 11.09. The thresholds are as follows: Strongly Undervalued below 4.94, Undervalued between 4.94 and 8.02, Fairly Valued between 14.17 and 8.02, Overvalued between 14.17 and 17.25, and Strongly Overvalued above 17.25. The current Forward EV/EBITDA of 9.73 falls within the Historic Trend Line -Fairly Valued range.
12.04
EV/EBIT
Regeneron Pharmaceuticals Inc. (REGN) has a current EV/EBIT of 12.04. The 5-year average EV/EBIT is 12.10. The thresholds are as follows: Strongly Undervalued below 5.78, Undervalued between 5.78 and 8.94, Fairly Valued between 15.26 and 8.94, Overvalued between 15.26 and 18.41, and Strongly Overvalued above 18.41. The current Forward EV/EBIT of 12.04 falls within the Historic Trend Line -Fairly Valued range.
5.00
PS
Regeneron Pharmaceuticals Inc. (REGN) has a current PS of 5.00. The 5-year average PS is 5.67. The thresholds are as follows: Strongly Undervalued below 3.21, Undervalued between 3.21 and 4.44, Fairly Valued between 6.91 and 4.44, Overvalued between 6.91 and 8.14, and Strongly Overvalued above 8.14. The current Forward PS of 5.00 falls within the Historic Trend Line -Fairly Valued range.
13.90
P/OCF
Regeneron Pharmaceuticals Inc. (REGN) has a current P/OCF of 13.90. The 5-year average P/OCF is 15.41. The thresholds are as follows: Strongly Undervalued below 5.73, Undervalued between 5.73 and 10.57, Fairly Valued between 20.25 and 10.57, Overvalued between 20.25 and 25.09, and Strongly Overvalued above 25.09. The current Forward P/OCF of 13.90 falls within the Historic Trend Line -Fairly Valued range.
16.16
P/FCF
Regeneron Pharmaceuticals Inc. (REGN) has a current P/FCF of 16.16. The 5-year average P/FCF is 16.50. The thresholds are as follows: Strongly Undervalued below 2.69, Undervalued between 2.69 and 9.60, Fairly Valued between 23.41 and 9.60, Overvalued between 23.41 and 30.32, and Strongly Overvalued above 30.32. The current Forward P/FCF of 16.16 falls within the Historic Trend Line -Fairly Valued range.
Regeneron Pharmaceuticals Inc (REGN) has a current Price-to-Book (P/B) ratio of 2.40. Compared to its 3-year average P/B ratio of 3.21 , the current P/B ratio is approximately -25.12% higher. Relative to its 5-year average P/B ratio of 3.50, the current P/B ratio is about -31.29% higher. Regeneron Pharmaceuticals Inc (REGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 4.78%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 5.74% , the current FCF yield is about -100.00% lower.
2.40
P/B
Median3y
3.21
Median5y
3.50
5.69
FCF Yield
Median3y
4.78
Median5y
5.74
Competitors Valuation Multiple
The average P/S ratio for REGN's competitors is 2.23, providing a benchmark for relative valuation. Regeneron Pharmaceuticals Inc Corp (REGN) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 0.90%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of REGN increased by 1.47% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 36.03 to 38.89.
The secondary factor is the Revenue Growth, contributed 0.90%to the performance.
Overall, the performance of REGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Regeneron Pharmaceuticals Inc (REGN) currently overvalued or undervalued?
What is Regeneron Pharmaceuticals Inc (REGN) fair value?
How does REGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Regeneron Pharmaceuticals Inc (REGN) as of Dec 05 2025?
What is the current FCF Yield for Regeneron Pharmaceuticals Inc (REGN) as of Dec 05 2025?
What is the current Forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN) as of Dec 05 2025?